Clinical Trials & Medical Discoveries

RZNOMICS Inc. received FDA approval to initiate clinical development of trans-splicing ribozyme-based RNA editing technology in Glioblastoma Multiforme Patients

by

SEONGNAM, South Korea, May 19, 2023 /PRNewswire/ — Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, recently received Phase 1/2a IND approval from the U.S FDA on May 6th for its Glioblastoma Multiforme (GBM) treatment called RZ-001 and thus has achieved an important milestone for the company and … Read more

Positive Results from Interim Analysis of ‘GEN-001’ Plus avelumab (Bavencio®) Phase II Trial

by

SEOUL, South Korea, May 19, 2023 /PRNewswire/ — Genome & Company (CEO: Pae, Jisoo), a global leading microbiome therapeutics developer, announced that this phase II trial (NCT05419362) will continue without modifications to move on to the second stage, based on the positive result of the interim analysis. Using a single-strain bacteria in combination with avelumab (Bavencio®) … Read more

EuroPCR 2023 | 6 Month Outcome of the SMART Study: satisfactory BP control achieved with reduced medication burden

by

PARIS, May 19, 2023 /PRNewswire/ — On May 17th 2023, the six-month result of the SMART Study (Sympathetic Mapping/Ablation Renal nerves for Treatment of hypertension Trial; NCT02761811) was released on the Late Breaking Clinical Trial conference, reporting ground-breaking findings in the field of hypertension. With Professor Huo Yong as the leading investigator and SyMap Medical (Suzhou) … Read more

Sebela Women’s Health Announces Positive Phase 3 Data for its Investigational, Next-Generation, Hormone-Free, Low-Dose Copper Intrauterine Device (IUD)

by

If approved by the U.S. Food and Drug Administration, this newly designed, low-dose copper IUD could be the first hormone-free IUD in almost 40 years ROSWELL, Ga., May 18, 2023 /PRNewswire/ — Sebela Women’s Health Inc., a part of Sebela Pharmaceuticals, today announced positive results of a Phase 3 study demonstrating that investigational Copper 175 … Read more

Sector to Reach $2.3 Billion by 2027 at a 14% CAGR

by

DUBLIN, May 18, 2023 /PRNewswire/ — The “Minimal Residual Disease Testing Market by Technology (PCR, Flow Cytometry, NGS), Application (Leukemia, Lymphoma, Solid Tumors), End User(Hospitals, Specialty Clinics, Diagnostic Labs, Research and Academic Institutes) & Region – Global Forecast to 2027” report has been added to  ResearchAndMarkets.com’s offering. The global minimal residual disease testing market is … Read more

At a CAGR of 6.19% ,Global Joint Reconstruction Market to Grow Exponentially by 2029- Brandessence Market Research

by

LONDON, May 18, 2023 /PRNewswire/ — Joint aches and related disorders are very common, especially among the older adults. Throughout our lives, a high pressure is applied on our joints to carry out various mobility activities which in turn weakens the. Apart from that, accidents and other injuries also lead to joint disorders. With rapid … Read more

Navrogen Announces Publication of NAV-001 Antibody-Drug Conjugate Development and Efficacy in Humoral Immunosuppressed Cancers

by

The publication in PLOS ONE shows that NAV-001 has robust single-dose efficacy against multiple mesothelin-expressing cancers and that tumor-produced Humoral Immunology-Oncology (HIO) factors negatively impact antibody drug internalization and efficacy. CHEYNEY, Pa., May 18, 2023 /PRNewswire/ — Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announces today a publication describing … Read more

Affinia Therapeutics Presents New Preclinical Data on Novel AAV Capsids for Skeletal Muscle, Cardiac Muscle, and CNS at the American Society of Gene & Cell Therapy 26TH Annual Meeting

by

WALTHAM, Mass., May 18, 2023 /PRNewswire/ — Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for both rare and prevalent devastating diseases, today announced the presentation of new preclinical data on novel AAV capsids for skeletal muscle, cardiac muscle, and central nervous system (CNS). This research will be presented in an oral session today at 1:30pm PT … Read more

BridGene Biosciences to Present at Hippo Pathway Targeted Drug Development Summit

by

SAN JOSE, Calif., May 18, 2023 /PRNewswire/ — BridGene Biosciences, Inc., a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high-value, traditionally undruggable targets, announced that Wolf Wiedemeyer, Ph.D., head of biology at BridGene, will be giving a presentation, titled “A Covalent TEAD Inhibitor with Exceptional Anti-cancer Activity & … Read more

EXOSOME DIAGNOSTICS RELEASES INTERIM RESULTS FROM CLINICAL STUDY OF PROSTATE CANCER RISK TEST

by

Halfway through 5-year study, ExoDx Prostate Test offers more accurate stratification of high- and low-risk patients compared to standard of care MINNEAPOLIS, May 18, 2023 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported interim results from a previously published prospective, randomized study of more than 1,000 patients … Read more